![Patricia L. Novak](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patricia L. Novak
Corporate Officer/Principal chez
University of California, Irvine
Profil
Patricia L.
Novak is Vice President of Program Development for Cardium Therapeutics, Inc., which she joined in November 2005.
She was Executive Director of Program Management and R&D for Metabasis Therapeutics and Vice President of Program Management for Collateral Therapeutics from 2000 to 2003 and Senior Director of Program Management from 1997 to 2000.
From 1991 to 1997, Dr. Novak was Director of Research and Development Planning and Project Management for Gensia, Inc. and Clinical Project Manager of Alpha Therapeutic Corporation from 1987 to 1991.
She received a PhD in Biological Sciences from the University of California, Irvine.
Postes actifs de Patricia L. Novak
| Sociétés | Poste | Début |
|---|---|---|
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Anciens postes connus de Patricia L. Novak
| Sociétés | Poste | Fin |
|---|---|---|
Cardium Therapeutics, Inc. /Old/
 Cardium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Develops therapeutics and treatments for coronary artery disease and heart attacks | Corporate Officer/Principal | 23/01/2006 |
Collateral Therapeutics, Inc.
 Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Discovers, develops and commercializes non-surgical gene therapy products | Corporate Officer/Principal | 01/01/2003 |
SICOR, Inc.
 SICOR, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Corporate Officer/Principal | 01/01/1997 |
Alpha Therapeutic Corp.
 Alpha Therapeutic Corp. BiotechnologyHealth Technology Develops of plasma derived products | Corporate Officer/Principal | 01/01/1991 |
Taxus Cardium Pharmaceuticals Group, Inc.
 Taxus Cardium Pharmaceuticals Group, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops and commercializes angiogenic gene therapy products for cardiovascular disease | Corporate Officer/Principal | - |
Formation de Patricia L. Novak
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
87
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Discovers, develops and commercializes non-surgical gene therapy products | Commercial Services |
SICOR, Inc.
SICOR, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
Metabasis Therapeutics, Inc.
 Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs | Health Technology |
Cardium Therapeutics, Inc. /Old/
Cardium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Develops therapeutics and treatments for coronary artery disease and heart attacks | Commercial Services |
Alpha Therapeutic Corp.
Alpha Therapeutic Corp. BiotechnologyHealth Technology Develops of plasma derived products | Health Technology |
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Taxus Cardium Pharmaceuticals Group, Inc.
Taxus Cardium Pharmaceuticals Group, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops and commercializes angiogenic gene therapy products for cardiovascular disease | Health Technology |
